ATE89737T1 - Behandlung von leukozytstoerungen mit gm-csf. - Google Patents

Behandlung von leukozytstoerungen mit gm-csf.

Info

Publication number
ATE89737T1
ATE89737T1 AT90300840T AT90300840T ATE89737T1 AT E89737 T1 ATE89737 T1 AT E89737T1 AT 90300840 T AT90300840 T AT 90300840T AT 90300840 T AT90300840 T AT 90300840T AT E89737 T1 ATE89737 T1 AT E89737T1
Authority
AT
Austria
Prior art keywords
csf
dysfunction
treating
treatment
leukocyte
Prior art date
Application number
AT90300840T
Other languages
English (en)
Inventor
Eric M Bonnem
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ATE89737T1 publication Critical patent/ATE89737T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • External Artificial Organs (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT90300840T 1989-01-30 1990-01-26 Behandlung von leukozytstoerungen mit gm-csf. ATE89737T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30439189A 1989-01-30 1989-01-30

Publications (1)

Publication Number Publication Date
ATE89737T1 true ATE89737T1 (de) 1993-06-15

Family

ID=23176323

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90300840T ATE89737T1 (de) 1989-01-30 1990-01-26 Behandlung von leukozytstoerungen mit gm-csf.

Country Status (21)

Country Link
US (1) US5178855A (de)
EP (2) EP0455726A1 (de)
JP (1) JPH0651640B2 (de)
KR (1) KR0137361B1 (de)
AT (1) ATE89737T1 (de)
AU (1) AU633054B2 (de)
CA (1) CA2045605C (de)
DE (1) DE69001686T2 (de)
DK (1) DK0382381T3 (de)
ES (1) ES2055314T3 (de)
FI (1) FI913625A7 (de)
HK (1) HK46196A (de)
HU (1) HU207229B (de)
IE (1) IE64234B1 (de)
IL (1) IL93219A (de)
MY (1) MY105798A (de)
NZ (1) NZ243953A (de)
OA (1) OA09509A (de)
PT (1) PT92995B (de)
WO (1) WO1990008554A1 (de)
ZA (1) ZA90600B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992014480A1 (en) * 1991-02-22 1992-09-03 Amgen Inc. Use of gm-csf and g-csf to promote accelerated wound healing
GB9120304D0 (en) * 1991-09-24 1991-11-06 Erba Carlo Spa Stable pharmaceutical compositions containing a granulocyte macrophage colony stimulating factor
WO1994028919A1 (fr) * 1993-06-08 1994-12-22 Ajinomoto Co., Inc. Accelerateur de la proliferation des cellules hematopietiques
US5777193A (en) * 1994-03-04 1998-07-07 Ludwig Institute For Cancer Research Animals with targeted gene disruption
US5942253A (en) 1995-10-12 1999-08-24 Immunex Corporation Prolonged release of GM-CSF
US6753165B1 (en) * 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
US7153943B2 (en) * 1997-07-14 2006-12-26 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins, and methods of use thereof
US20080076706A1 (en) 1997-07-14 2008-03-27 Bolder Biotechnology, Inc. Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
US8288126B2 (en) 1999-01-14 2012-10-16 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
US6911204B2 (en) 2000-08-11 2005-06-28 Favrille, Inc. Method and composition for altering a B cell mediated pathology
CA2673049C (en) * 2006-12-22 2016-02-23 Novadel Pharma Inc. Stable anti-nausea oral spray formulations and methods
US7841878B2 (en) * 2007-08-09 2010-11-30 Haworth, Inc. Modular electrical distribution system for a building

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5078996A (en) * 1985-08-16 1992-01-07 Immunex Corporation Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
AU606585B2 (en) * 1985-10-03 1991-02-14 Biogen, Inc. Human granulocyte-macrophage colony stimulating factor-like polypeptides and processes for producing them in high yields in microbial cells
JPH0618778B2 (ja) * 1985-10-04 1994-03-16 中外製薬株式会社 白血球減少症治療剤
DE3686582T2 (de) * 1985-11-27 1993-01-28 Genetics Inst Behandlung einer krankheit vom aids-typ.
EP0307402B1 (de) * 1986-05-06 1993-08-11 Genetics Institute, Inc. Herstellung von m-csf
US5162111A (en) * 1986-07-30 1992-11-10 Grabstein Kenneth H Treatment of bacterial diseases with granulocyte-macrophage colony stimulating factor
EP0276846A3 (de) * 1987-01-29 1989-07-26 Zymogenetics, Inc. Derivate des koloniestimulierenden Faktors
EP0386109A1 (de) * 1987-11-12 1990-09-12 Schering Corporation Knochenbildungssbeschleunigung durch gm-csf

Also Published As

Publication number Publication date
JPH0651640B2 (ja) 1994-07-06
WO1990008554A1 (en) 1990-08-09
IL93219A0 (en) 1990-11-05
US5178855A (en) 1993-01-12
ZA90600B (en) 1990-10-31
AU5048890A (en) 1990-08-24
HU207229B (en) 1993-03-29
PT92995B (pt) 1995-12-29
DE69001686T2 (de) 1993-09-02
HUT57607A (en) 1991-12-30
IL93219A (en) 1998-12-27
OA09509A (en) 1992-11-15
DK0382381T3 (da) 1993-07-12
AU633054B2 (en) 1993-01-21
EP0382381B1 (de) 1993-05-26
IE900318L (en) 1990-07-30
KR0137361B1 (ko) 1998-04-25
KR910700069A (ko) 1991-03-13
FI913625A0 (fi) 1991-07-30
MY105798A (en) 1995-01-30
NZ243953A (en) 1997-06-24
JPH03504980A (ja) 1991-10-31
CA2045605C (en) 1997-02-11
HK46196A (en) 1996-03-22
IE64234B1 (en) 1995-07-26
PT92995A (pt) 1990-07-31
CA2045605A1 (en) 1990-07-31
EP0455726A1 (de) 1991-11-13
ES2055314T3 (es) 1994-08-16
FI913625A7 (fi) 1991-07-30
DE69001686D1 (de) 1993-07-01
EP0382381A1 (de) 1990-08-16

Similar Documents

Publication Publication Date Title
DE69333321D1 (de) Verwendung eines Consensus-Interferons zur Reduzierung der Nebeneffekte in der Interferon Behandlung von viralen Hepatiten.
BG60253B1 (bg) Човешки тъканен плазминогенен активатор
DE69230046D1 (de) 2-Bromomelatonin zur Behandlung von Schlafstörungen
DE69012591D1 (de) Verwendung von Nikotin zur Herstellung eines Kit zur Behandlung von Krankheitszuständen, die auf eine Nikotinbehandlung ansprechen.
IT8419266A1 (it) Dispositivo per generare calore in tessuti" del corpo umano e procedimento di cenerazione di calore, particolarmente per la cura di tumori
ATE158182T1 (de) Arzneimittel sowie deren herstellung und deren verwendung bei der bekämpfung von schmerzen und/oder entzündungen an tieren und menschen
EP0317568A4 (de) Verwendung von Granulozyt-Makrophagen-Kolonie Erregenden Faktor zur Herstellung eines Medikaments zur Behandlung von Bakterieller krankheiten.
ATE89737T1 (de) Behandlung von leukozytstoerungen mit gm-csf.
GR3015765T3 (en) A novel thrombomodulin-like glycoprotein obtainable from urine.
KR890001580A (ko) B형 간염 바이러스에 의해 유발되는 염증 질환을 치료하는 이중가닥 rna를 함유하는 약물
IT9041503A0 (it) Dispositivo per la cura chirurgica dell'ametropia
DE69623316D1 (de) Ctla-8 in kombination mit g-csf oder mit g-csf und il-6, und verwendung vom ctla-8 zur behandlung von infektionen
DE3750248D1 (de) Zubereitung und Behandlung der Haut mit Human-Leukocyten-Interferon.
KR870010871A (ko) 재조합 인체 알파 인터페론에 의한 기저세포 암종의 병소내적 치료방법
KR900701311A (ko) 재조합 사람 α-인터페론을 병소내로 투여하여 편평세포 암을 치료하는 방법
IT1246050B (it) Impiego dell'eptastigmina nella terapia dell'ictus cerebrale.
KR920009403A (ko) 수면장해 치료용 이미다조벤조디아제핀
周荣兴 et al. THE EFFECT OF ACUPUNCTURE ON THE PHAGOCYTIC ACTIVITY OF HUMAN LEUKOCYTES
RU96115809A (ru) Способ лечения сочетанной челюстно-мозговой травмы
IT9041714A0 (it) Linfa del libro dell'abete rosso (abies picea) per la cura di malattie neoplastiche e da virus in genere
RU94002713A (ru) Способ лечения детей с синдромом удлиненного интервала qт (романо-уорда)
ATE88090T1 (de) Verwendung von acetyl-d-carnitin zur therapeutischen behandlung von glaukom.
RU94001389A (ru) Способ лечения псориаза
RU93021719A (ru) Способ лечения отслойки сетчатки

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee